From blockbuster to “nichebuster”: how a flawed legislation helped create a new profit model for the drug industry

After reaping 12 years of orphan exclusivity rewards in Europe, company executives at Celgene (now Bristol-Myers Squibb) were on the verge of celebrating yet another monopoly extension. If the…


Read Original Article: From blockbuster to “nichebuster”: how a flawed legislation helped create a new profit model for the drug industry »